論文（英文）

• Kawashima M, Murakawa T, Shinozaki T, Ichinose J, Hino H, Konoeda C, Tsuchiya T, Murayama T, Nagayama K, Nitadori JI, Anraku M, Nakajima J. Significance of the Glasgow Prognostic Score as a prognostic indicator for lung cancer surgery. Interact Cardiovasc Thorac Surg. 2015;21(5):637-43.
• Taniguchi Y, Fujiwara Y, Nofuji Y, Nishi M, Murayama H, Seino S, Tajima R, Matsuyama Y, Shinkai S. Prospective study of arterial stiffness and subsequent cognitive decline among community-dwelling older Japanese. Journal of Epidemiology 2015; 25(9): 592-599.
• Sugimoto T, Umeda M, Shinozaki T, Naruse T, Miyamoto Y. Sources of perceived social support associated with reduced psychological distress at one year after the Great East Japan Earthquake: A nationwide cross-sectional survey in 2012. Psychiatry Clin Neurosci. 2015; 69(9):580–586.
• Kuramitsu S, Hiromasa T, Enomoto S, Shinozaki T, Iwabuchi M, Mazaki T, Domei T, Yamaji K, Soga Y, Hyodo M, Shirai S, Ando K. Incidence and clinical impact of stent fracture after the PROMUS element platinum chromium everolimus-eluting stent implantation. JACC Cardiovasc Interv. 2015;8(9):1180-8.
• Tada N, Kawai K, Tsuno NH, Ishihara S, Yamaguchi H, Sunami E, Kitayama J, Oba K, Watanabe T. Prediction of the preoperative chemoradiotherapy response for rectal cancer by peripheral blood lymphocyte subsets. World J Surg Oncol 2015;13:30
• Matsushima M, Yabe I, Oba K, Sakushima K, Mito Y, Takei A, Houzen H, Tsuzaka K, Yoshida K, Maruo Y, Sasaki H. Comparison of Different Symptom Assessment Scales for Multiple System Atrophy. Cerebellum. 2015 Jun 21.
• Kotaka M, Yoshino T, Oba K, Shinozaki K, Touyama T, Manaka D, Matsui T, Ishigure K, Hasegawa J, Inoue K, Goto K, Sakamoto J, Saji S, Ohtsu A, Watanabe T. Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial). Cancer Chemother Pharmacol 2015;76:75-84.
• Abe Y, Kawakami H, Oba K, Hayashi T, Yasuda I, Mukai T, Isayama H, Ishiwatari H, Doi S, Nakashima M, Yamamoto N, Kuwatani M, Mitsuhashi T, Hasegawa T, Hirose Y, Yamada T, Tanaka M, Sakamoto N; Japan EUS-FNA Stylet Study Group. Effect of a stylet on a histological specimen in EUS-guided fine-needle tissue acquisition by using 22-gauge needles: a multicenter, prospective, randomized, controlled trial. Gastrointest Endosc 2015;82:837-844.
• Takeuchi Y, Kajiyama K, Ishiguro C, Uyama Y. Atypical antipsychotics and the risk of hyperlipidemia: A sequence symmetry analysis. Drug Saf. 2015; 38(7): 641–650.
• Jinnouchi H, Kuramitsu S, Shinozaki T, Kobayashi Y, Hiromasa T, Morinaga T, Mazaki T, Sakakura K, Soga Y, Hyodo M, Shirai S, Ando K. Two-year clinical outcomes of newer-generation drug-eluting stent implantation following rotational atherectomy for heavily calcified lesions. Circ J. 2015;79(9):1938-43.
• Sakuhara Y, Nishio S, Morita K, Abo D, Hasegawa Y, Yuasa N, Mochizuki T, Soyama T, Oba K, Shirato H, Kudo K. Transcatheter Arterial Embolization with Ethanol Injection in Symptomatic Patients with Enlarged Polycystic Kidneys. Radiology 2015:141637.
• Iwamoto S, Takahashi T, Tamagawa H, Nakamura M, Munemoto Y, Kato T, Hata T, Denda T, Morita Y, Inukai M, Kunieda K, Nagata N, Kurachi K, Ina K, Ooshiro M, Shimoyama T, Baba H, Oba K, Sakamoto J, Mishima H. FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study. Ann Oncol 2015 Apr 23.
• Komatsu Y, Okita K, Yuki S, Furuhata T, Fukushima H, Masuko H, Kawamoto Y, Isobe H, Miyagishima T, Sasaki K, Nakamura M, Ohsaki Y, Nakajima J, Tateyama M, Eto K, Minami S, Yokoyama R, Iwanaga I, Shibuya H, Kudo M, Oba K, Takahashi Y. An open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron. Cancer Sci 2015;106:891-5.
• Buyse M, Molenberghs G, Paoletti X, Oba K, Alonso A, Van der Elst W, Burzykowski T. Statistical evaluation of surrogate endpoints with examples from cancer clinical trials. Biom J. 2015 Feb 12. doi: 10.1002/bimj.201400049.
• Murai K, Akagi T, Shimosegawa K, Sugawara T, Ishizawa K, Ito S, Murai K, Motegi M, Yokoyama H, Noji H, Tajima K, Kimura J, Chou T, Ogawa K, Harigae H, Kubo K, Oba K, Sakamoto J, Ishida Y. A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria. Eur J Haematol. 2015 Feb 19. doi: 10.1111/ejh.12536.
• Shinohara N, Obara W, Tatsugami K, Naito S, Kamba T, Takahashi M, Murai S, Abe T, Oba K, Naito S. Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy. Cancer Sci. 2015 Feb 25. doi: 10.1111/cas.12646.
• Kobayashi Y, Komatsu Y, Yuki S, Fukushima H, Sasaki T, Iwanaga I, Uebayashi M, Okuda H, Kusumi T, Miyagishima T, Sogabe S, Tateyama M, Hatanaka K, Tsuji Y, Nakamura M, Konno J, Yamamoto F, Onodera M, Iwai K, Sakata Y, Abe R, Oba K, Sakamoto N. Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP. Future Oncol 2015;11:617-27.
• Fukushima A, Kinugawa S, Homma T, Masaki Y, Furihata T, Yokota T, Matsushima S, Takada S, Kadoguchi T, Oba K, Okita K, Tsutsui H. Serum Brain-Derived Neurotrophic Factor Level Predicts Adverse Clinical Outcomes in Patients with Heart Failure. J Card Fail 2015 Jan 29. doi: 10.1016/j.cardfail.2015.01.003.
• Kitai S, Kudo M, Izumi N, Kaneko S, Ku Y, Kokudo N, Sakamoto M, Takayama T, Nakashima O, Kadoya M, Matsuyama Y, Matsunaga T. Validation of three staging systems for hepatocellular carcinoma (JIS score, biomarker-combined JIS score and BCLC system) in 4,649 cases from a Japanese nationwide survey. Digestive diseases 2014; 32(6):717-724.
• Otsuka M, Yokoi H, Matsuyama Y, Hayashi Y, Shiode N, Masaoka Y, Okimoto T, Tamekiyo H, Kawase T, Yamane K, Kagawa Y, Nakamura M, Muramatsu T, Nanto S; J-DESsERT investigators. Comparison of sirolimus- and paclitaxel-eluting stents in patients with moderate renal insufficiency: results from the J-DESsERT trial. Cardiovascular Revascularization Medicine 2014; 15: 323-328.

TOP